Medtronic to acquire CathWorks for FFRangio non‑invasive coronary physiology mapping
- Medtronic is acquiring CathWorks in a deal worth up to $585 million plus potential earn‑outs.
- FFRangio uses AI to deliver non‑invasive, full coronary physiological assessments from routine angiograms.
- Medtronic will integrate FFRangio into its coronary portfolio and leverage its commercial footprint to accelerate adoption.
Medtronic moves to acquire CathWorks to expand non‑invasive coronary diagnostics
FFRangio acquisition aims to reshape cath lab physiology mapping
Medtronic is exercising its option to acquire privately held CathWorks, the company says from Galway, Ireland on Feb. 3, 2026, in a deal valued at up to $585 million plus potential post‑close earn‑outs. The move follows a 2022 strategic partnership and co‑promotion agreement covering the FFRangio® System in the United States, Europe and Japan, where the technology is already commercially available. Medtronic frames the purchase as a targeted investment to broaden its cardiovascular pipeline and strengthen its interventional cardiology offerings.
Medtronic says the FFRangio system leverages artificial intelligence and advanced computational science to produce a physiological assessment of the entire coronary tree from routine coronary angiograms, avoiding the pressure wires and pharmacologic hyperemia required for traditional wire‑based fractional flow reserve (FFR). Company executives note that wire‑based FFR, despite evidence of clinical benefits and cost effectiveness, remains underused because it is invasive and provides measurements at a single transducer location. Medtronic’s coronary business leadership says co‑promotion experience shows FFRangio can provide real‑time, data‑driven information that supports individualized patient pathways from diagnosis to treatment.
The company is positioning the acquisition as a way to transform cath lab workflows by delivering broader physiologic mapping to inform revascularization decisions and reduce unnecessary percutaneous coronary interventions (PCI). Medtronic cites clinical studies demonstrating the FFRangio System’s diagnostic accuracy and promising outcomes as the basis for anticipated broader adoption. The deal is presented as aligning with Medtronic’s strategy to integrate less invasive diagnostics into its therapeutic platforms and to scale access to data‑driven tools across hospitals and health systems globally.
Broader industry context
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

